Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.
BACKGROUND
Data regarding the role of systemic therapy in patients with advanced well-differentiated/dedifferentiated liposarcomas (WDLPS/DDLPS) are limited.


METHODS
From 2000 to 2010, 208 patients with advanced WDLPS/DDLPS received chemotherapy in 11 participating institutions. Clinical and pathological data were collected by reviewing medical records.


RESULTS
Median age was 63 years (range 32-84). Combination chemotherapy was delivered in 85 cases (41%) and single agent in 123 cases (59%), respectively. One hundred and seventy-one patients (82%) received an anthracycline-containing regimen. Using RECIST, objective response was observed in 21 patients (12%), all treated with anthracyclines. Median progression-free survival (PFS) was 4.6 months [95% confidence interval (CI) 3.3-5.9]. On multivariate analysis, age and performance status (PS) were the sole factors significantly associated with poor PFS. Median overall survival (OS) was 15.2 months (95% CI 11.8 -18.7). On multivariate analysis, grade and PS were the sole factors significantly associated with OS.


CONCLUSIONS
Chemotherapy was associated with clinical benefit in 46% of patients with advanced WDLPS/DDLPS. OS remains poor, even though visceral metastatic disease is less frequent than in other sarcomas.
Department of Medical Oncology, Institut Bergonié, Bordeaux, France. italiano@bergonie.org
A
A
Italiano
M
M
Toulmonde
A
A
Cioffi
N
N
Penel
N
N
Isambert
E
E
Bompas
F
F
Duffaud
A
A
Patrikidou
B
B
Lortal
A
A
Le Cesne
J-Y
JY
Blay
R G
RG
Maki
G K
GK
Schwartz
C R
CR
Antonescu
S
S
Singer
J-M
JM
Coindre
B
B
Bui
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008080:Liposarcoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D011379:Prognosis; D016016:Proportional Hazards Models; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012189:Retrospective Studies; D016896:Treatment Outcome
D018943:Anthracyclines; D000970:Antineoplastic Agents